Amicus Therapeutics, Inc. 8-K Report: Key Insights for Investors on Feb 19, 2025

The extracted key information from the provided financial report section is as follows:

Entity Information:

Company Name: Amicus Therapeutics, Inc.
CIK: 0001178879
State of Incorporation: Delaware (DE)
SEC Central Index Key (CIK): 0001178879
Address: 47 Hulfish Street, Princeton, NJ 08542
Phone Number: 609-662-2000

Filing Details:

Form Type: 8-K
Filing Date: February 19, 2025
SEC File Number: 001-33497
Employer Identification Number (EIN): 71-0869350

Stock Information:

Class of Stock: Common Stock
Par Value: $0.01
Ticker Symbol: FOLD
Exchange: NASDAQ

Period Information:

Report Date: February 19, 2025
Context Period: The report is for a single day, with both the start and end date being February 19, 2025.

Units of Measurement:

Currency: USD
Shares: The report mentions shares, indicating that the financial data may relate to share price or share volume.

Insights:

The filing is an 8-K, which typically indicates a significant event or corporate change, such as mergers, acquisitions, or other events that might impact the company's financial condition or operations.
As Amicus Therapeutics is listed on NASDAQ under the ticker FOLD, this filing may be of interest to investors tracking the company's performance.
The report is very recent as it pertains to a future date (February 19, 2025), suggesting it could be a forward-looking statement or announcement regarding anticipated corporate activities.

This information could be crucial for stakeholders, investors, and analysts monitoring the company's developments and performance in the pharmaceutical industry.